Constipation
Conditions
Interventions
Observation group B:290 µg Linaclotide + 30ml Simethicone + 2 L PGEP
Observation group A:290 µg Linaclotide + 2 L PGEP
Control group:3L compound polyethylene glycol electrolyte solution
Sponsors
The People's Hospital of Jianyang City
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.It meets the diagnostic criteria of Rome IV constipation; 2.Age: 18 ~ 70 years old.
Exclusion criteria
Exclusion criteria: 1. Patients with toxic enteritis, megacolon, intestinal volvulus, gastrointestinal obstruction, gastric retention, gastrointestinal bleeding, gastrointestinal perforation, etc.; 2. Individuals known to be allergic to the components of the study drug; 3. Those with a history of malignant tumors, radiotherapy or chemotherapy, or colorectal surgery; 4. Individuals with significant coagulation disorders, platelet abnormalities, or severe hematologic diseases; 5. Those with a history of mental illness; 6. Patients with severe heart, lung, liver, or kidney diseases; 7. Those taking any drugs that may affect gastrointestinal motility, PPI, NSAIDs, or antibiotics (within 4 weeks prior to enrollment), or probiotics (within 2 weeks prior to enrollment); 8. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The lesion detection rate;The willingness to repeat examination;The incidence of adverse reactions;Intestinal cleaning effect; | — |
Secondary
| Measure | Time frame |
|---|---|
| The frequency of defecation;The first defecation interval; | — |
Countries
China
Contacts
Public ContactLiao Jinwen
The People's Hospital of Jianyang City
Outcome results
None listed